ID   CHP-126
AC   CVCL_1123
SY   CHP 126; CHP126
DR   BTO; BTO:0005254
DR   CLO; CLO_0002472
DR   CLO; CLO_0050266
DR   CLDB; cl776
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN01821621
DR   BioSample; SAMN03473117
DR   BioSample; SAMN10988481
DR   CCLE; CHP126_AUTONOMIC_GANGLIA
DR   Cell_Model_Passport; SIDM00286
DR   ChEMBL-Cells; CHEMBL3308252
DR   ChEMBL-Targets; CHEMBL2366137
DR   CLS; 300432/NA
DR   Cosmic; 688062
DR   Cosmic; 910567
DR   Cosmic; 1019935
DR   Cosmic; 2485942
DR   Cosmic-CLP; 910567
DR   DepMap; ACH-000136
DR   DSMZ; ACC-304
DR   GDSC; 910567
DR   GEO; GSM563360
DR   GEO; GSM886929
DR   GEO; GSM887995
DR   GEO; GSM1366403
DR   GEO; GSM1669676
DR   LiGeA; CCLE_141
DR   LINCS_LDP; LCL-1973
DR   PharmacoDB; CHP126_198_2019
DR   RCB; RCB0486
DR   Wikidata; Q54813263
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=10079;
RX   PubMed=17466;
RX   PubMed=6888561;
RX   PubMed=7139592;
RX   PubMed=16822308;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 44.5 hours (PubMed=10079).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.41%; East Asian, North=1.27%; East Asian, South=0%; South Asian=0.75%; European, North=65.66%; European, South=31.9% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=11416159; PubMed=25877200; RCB
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8,9
ST   D16S539: 12,13
ST   D18S51: 13,16.1
ST   D19S433: 13.2,14
ST   D21S11: 30
ST   D2S1338: 17,24
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 11,14
ST   D8S1179: 12,15
ST   FGA: 19,20
ST   Penta D: 10,12
ST   Penta E: 12,15
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C3270; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_9506 ! CHP-126BL
SX   Female
AG   1Y2M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 27
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=10079;
RA   Schlesinger H.R., Gerson J.M., Moorhead P.S., Maguire H., Hummeler K.;
RT   "Establishment and characterization of human neuroblastoma cell
RT   lines.";
RL   Cancer Res. 36:3094-3100(1976).
//
RX   PubMed=17466; DOI=10.1002/1097-0142(197706)39:6<2508::AID-CNCR2820390630>3.0.CO;2-X;
RA   Gerson J.M., Schlesinger H.R., Sereni P., Moorhead P.S., Hummeler K.;
RT   "Isolation and characterization of a neuroblastoma cell line from
RT   peripheral blood in a patient with disseminated disease.";
RL   Cancer 39:2508-2512(1977).
//
RX   PubMed=6888561; DOI=10.1038/305245a0;
RA   Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M.,
RA   Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.;
RT   "Amplified DNA with limited homology to myc cellular oncogene is
RT   shared by human neuroblastoma cell lines and a neuroblastoma tumour.";
RL   Nature 305:245-248(1983).
//
RX   PubMed=7139592; DOI=10.1016/0165-4608(82)90105-4;
RA   Gilbert F., Balaban G., Moorhead P.S., Bianchi D., Schlesinger H.R.;
RT   "Abnormalities of chromosome 1p in human neuroblastoma tumors and cell
RT   lines.";
RL   Cancer Genet. Cytogenet. 7:33-42(1982).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177-177(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//